BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, January 10, 2025
See today's BioWorld
Home
» Bioshin rakes in $60M in series A funding led by Orbimed
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Bioshin rakes in $60M in series A funding led by Orbimed
Sep. 30, 2020
By
Gina Lee
No Comments
HONG KONG – Shanghai-based Bioshin Ltd., the Asia-Pacific arm of New Haven, Conn.-based Biohaven Pharmaceutical Holding Co. Ltd., has added $60 million to its war chest via a series A investment.
BioWorld
Financings
Neurology/psychiatric
Series A
Asia-Pacific
